FDA Approves Roche's Ventana PD-L1 Assay for Lung Cancer Treatment
Most common form of lung cancer is non-small cell lung cancer, and it also has the lowest rate of survival rate among cancers. Recently, the FDA approved Roche to use Ventana PD-L1 assay in combination with the company’s Tecentriq (atezolizumab) for treating metastatic non-small cell lung cancer.
Roche's PD-L1 assay is the first to assess PD-L1 expression using both tumor cell and immune cell staining which will help the physician to determine the patient’s survival benefit from the treatment with Tecentriq. Roche stated to continue to seek regulatory approval for the Ventana PD-L1 assay in conjunction with Tecentriq for other cancer indications and seek the approval globally.
Source:
http://www.fiercebiotech.com/medical-devices/fda-gives-roche-s-ventana-pd-l1-assay-approval-lung-cancer-treatment